| NORDIC BIOSCIENCE A/S Patent applications |
| Patent application number | Title | Published |
|---|
| 20120046224 | TREATMENT OF DIABETES AND METABOLIC SYNDROME - Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels. | 02-23-2012 |
| 20120045781 | PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described. | 02-23-2012 |
| 20100323377 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 12-23-2010 |
| 20100317023 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies. | 12-16-2010 |
| 20100209940 | FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: | 08-19-2010 |
| 20090216094 | Method of deriving a quantitative measure of a degree of calcification of an aorta - A method of deriving a quantitative measure of a degree of calcification of a blood vessel such as an aorta by processing an image such as an X-ray image of at least a part of the blood vessel containing said calcification comprises: taking a starting set of digital data representative of an image of at least part of a blood vessel containing a calcification set against a background; estimating the boundary of the calcification; using inpainting to replace digital data in said starting set representing the calcification with data extrapolating the boundary of the background to extend over the area of calcification, and so generating an inpainted set of digital data; and computing the difference between the starting set of digital data and the inpainted set of digital data to obtain a quantitative measure of the degree of calcification of the blood vessel. | 08-27-2009 |
| 20090190815 | Cartilage Curvature - A method for the analysis of three dimensional scan data representing an articular cartilage is provided to extract a quantitative parameter indicative of joint pathology. A measure of local curvature of the cartilage is determined within a region of interest. The value of the quantitative parameter of this joint derived from this measure is compared with the value of a similar quantitative parameter previously established in respect of healthy joints and/or joints characterised by a pathology. | 07-30-2009 |
